LCTX · Lineage Cell Therapeutics, Inc.

$1.14 +0.04 (+3.64%) At close · Jul 21

Market Cap

$275.47M

249.30M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brian Culley	CEO	$551,900	$262,200	—	$521,563	—	$14,250	$1,349,913
Chase C. Leavitt	General Counsel	$346,300	$131,600	—	$260,802	—	$14,250	$752,952
Brandi Roberts	CFO	$393,200	—	—	$260,802	—	$14,250	$668,252

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brandi Roberts	CFO	$376,137	$169,900	—	$397,948	—	$3,978	$947,963
Brian Culley	CEO	$535,800	$214,300	—	—	—	$22,642	$772,742
Edward D. Wirth	III, M.D., Ph.D. Former Chief Medical Officer	$285,000	—	—	$379,754	—	$30,038	$694,792
Chase C. Leavitt	General Counsel	$210,146	$102,100	—	$277,310	—	$9,542	$599,098

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Brian Culley	CEO	$154,923	$70,000	$693,000	$1,917,320	—	$27,464	$2,862,707

Key facts CIK 876343 CUSIP 53566P109 13F (30d) 9 filings 9 filers Visit website Investor relations